Statement in response to the EU Council ratifying the Brexit transition deal

23 March 2018

Today’s agreement on a transition period is welcome news for […]

European health community issues key questions Article 50 negotiations must answer for patients and public health

8 March 2018

The European Health Community has warned that time is running […]

Supply chain commitment to tackling problem of medicine shortages

2 March 2018

IGBA congratulates the Australian government for maintaining their biologics naming convention and for strengthening pharmacovigilance

29 January 2018

2018 – A year of unprecedented challenges and opportunities for pharmaceutical regulatory systems

25 January 2018

This week in London, Medicines for Europe gathers regulators and […]

Vigilance saves lives! More focus needed on sustainability and patient engagement

24 January 2018

National authorities, regulators, industry leaders and key stakeholders gathered in […]

Report shows life sciences industry alliance is taking action to curb antimicrobial resistance, with more to come

18 January 2018

Geneva, 18 January 2018 – Today, the AMR Industry Alliance […]

The associations representing the European and British life science industry (AESGP, ABPI, BGMA, BIA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today launched a joint policy document on the potential impact of the United Kingdom’s exit from the European Union

14 December 2017

Today, organisations representing the life science industry in the EU […]

Europe’s life science industry urges the UK and EU27 to safeguard patients’ access to medicines with a clear transition period and a future cooperation agreement after Brexit

28 November 2017

The associations representing the European and British life science industry […]

Medicines for Europe calls for greater cooperation on value added medicines to improve patient-centric innovation

22 November 2017

The 1st Value Added Medicines conference organised by the Value […]